Explore All Access
Check if your research matches the topics covered in Investigational New Drugs?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Investigational New Drugs : Impact Factor & More
eISSN: 1573-0646pISSN: 0167-6997
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Investigational New Drugs Key Metrics
CiteScore 
6.2
Eigenfactor
0.005 - 0.01
H-Index
94
Impact Factor
< 5
SJR
Q1Oncology
SNIP
0.85
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months62%
4 to 6 months33%
7 to 9 months2%
Above 9 months3%
Did you find this useful?
Topics Covered on Investigational New Drugs
Drug discovery
Cancer
Lung cancer
Maximum tolerated dose
Whole blood
Bioinformatics analysis
Hepatocellular carcinoma
Toxicity
Signal transduction
Breast cancer
Immunotherapy
Oral administration
Epidermal growth factor receptor
Nivolumab
Chemoradiotherapy
Overall survival
Erlotinib
Microscale thermophoresis
Mesothelioma
Progression-free survival
Investigational New Drugs Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Investigational New Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Investigational New Drugs
Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.
- 6 Nov 2024
- Investigational new drugs
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.
- 4 Nov 2024
- Investigational new drugs
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
- 26 Oct 2024
- Investigational new drugs
Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review.
- 21 Oct 2024
- Investigational new drugs
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models.
- 21 Oct 2024
- Investigational new drugs
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
- 10 Oct 2024
- Investigational new drugs
Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.
- 6 Nov 2024
- Investigational new drugs
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.
- 4 Nov 2024
- Investigational new drugs
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
- 26 Oct 2024
- Investigational new drugs
Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review.
- 21 Oct 2024
- Investigational new drugs
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models.
- 21 Oct 2024
- Investigational new drugs
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
- 10 Oct 2024
- Investigational new drugs
Compare Similar Journals with Investigational New Drugs
Select Journals to Compare with Investigational New Drugs
Total journals - 10
You can select up to 3 Journals at a time
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Annals of Oncology
Publisher: ELSEVIER
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Clinical Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Cancer Chemotherapy and Pharmacology
Publisher: SPRINGER
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Cancers
Publisher: MDPI
European Journal of Cancer
Publisher: ELSEVIER SCI LTD
BMC Cancer
Publisher: BMC
Journal for ImmunoTherapy of Cancer
Publisher: BMJ PUBLISHING GROUP
0 Journals Selected to compare with
Investigational New Drugs
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Investigational New Drugs
How long has Investigational New Drugs been actively publishing? 
Investigational New Drugs has been in operation since 1983 till date.
What is the publishing frequency of Investigational New Drugs?
Investigational New Drugs published with a Bi-monthly frequency.
How many articles did Investigational New Drugs publish last year?
In 2023, Investigational New Drugs publsihed 91 articles.
What is the eISSN & pISSN for Investigational New Drugs?
For Investigational New Drugs, eISSN is 1573-0646 and pISSN is 0167-6997.
What is Citescore for Investigational New Drugs?
Citescore for Investigational New Drugs is 6.2.
What is the H Index for Investigational New Drugs ?
H Index for Investigational New Drugs is 94.
What is SNIP score for Investigational New Drugs?
SNIP score for Investigational New Drugs is 0.85.
What is the SJR for Investigational New Drugs?
SJR for Investigational New Drugs is Q1.
Who is the publisher of Investigational New Drugs?
SPRINGER is the publisher of Investigational New Drugs.
